The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...